August 1969

Immunization With Live Attenuated Rubella Virus Vaccine (HPV-77)Clinical and Serological Results in Children and Adolescents in Israel

Author Affiliations

Jerusalem, Israel; Ness-Ziona, Israel
From the Department of Virology, Hebrew University-Hadassah Medical School (Dr. Goldblum), and the Division of Epidemiology, Ministry of Health (Dr. Swartz), Jerusalem, Israel; and the departments of virology (Drs. W. Klingberg and Goldwasser) and epidemiology (Dr. M. Klingberg), Israel Institute for Biological Research, Ness-Ziona, Israel.

Am J Dis Child. 1969;118(2):190-196. doi:10.1001/archpedi.1969.02100040192006

THE experience with live attenuated rubella virus vaccines which has accumulated in the last few years shows a clear need for a rubella vaccine that is not only safe and effective, but also has few or no side affects when recommended as a routine procedure. Age seems to affect the intensity of the clinical response to vaccine administration, and, since joint manifestations have been reported in adult women immunized with rubella vaccine,1-3 it was considered desirable to study the age effect further by investigating the clinical and serological reactions in a broad age spectrum of susceptible women.

For this purpose a field trial was initiated in Israel during the autumn and winter months of 1968 and 1969 which included a representative number of female subjects of various ages. The preliminary observations of the trial are presented in this report.

Materials and Methods  Study Group.—This group included 239 girls,

First Page Preview View Large
First page PDF preview
First page PDF preview